{
    "nctId": "NCT00615940",
    "briefTitle": "Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer",
    "officialTitle": "A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 132,
    "primaryOutcomeMeasure": "Efficacy in terms of progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females aged \u2265 18 years\n* Patients appropriate for palliative first-line, mono chemotherapy with capecitabine\n* Histological or cytological confirmed, non-inflammatory metastatic breast cancer\n* Availability of paraffin-embedded tumor tissue from the primary resection or biopsy of a metastatic lesion.\n* HER2-negative breast cancer\n* Complete staging within 2 weeks prior to randomization (4 weeks for bone scan).\n* Radiologically confirmed disease\n* ECOG performance status of \u2264 2\n* Ability to understand and willingness to voluntarily sign and date a written informed consent form before screening\n* Negative pregnancy test (urine or serum) within 3 days before first study drug for women of childbearing potential. Use of effective contraception during the study and for 3 months after stopping study drug treatment.\n* Normal organ and marrow function as defined by laboratory parameters (obtained within the screening period) within the following limits:\n\n  * neutrophils \\>= 1.5 x 109/L;\n  * platelets \\>= 100 x 109/L;\n  * hemoglobin \\>= 9.0 g/dL (5.6 mmol/L).\n  * total bilirubin \\<= 1.5 x upper limit of normal (ULN);\n  * aspartate aminotransferase (AST)/ALT \\<= 2.5 x ULN (\\< 5.0 x ULN for patients with liver metastases);\n  * serum creatinine \\<= 2 x ULN, or calculated creatinine clearance \\>45 mL/min according to Cockroft and Gault formula).\n\nExclusion Criteria:\n\n* Endocrine therapy completed within 2 weeks before the start of treatment (i.e. previous hormone therapy is allowed provided that there is a washout period of 2 weeks).\n* Prior chemotherapy or biologic therapy for metastatic disease.\n* Major surgery within 4 weeks prior to the start of treatment.\n* Other anti-cancer treatment (e.g. hormones) within 2 weeks before the start of treatment.\n* Treatment within 12 months with adjuvant 5-FU containing chemotherapy (regarded as indicating 5-FU resistance) and/or prior capecitabine therapy.\n* Radiation therapy. Palliative radiation of stable, non-target lesions more than 2 weeks before the start of treatment is allowed, provided patients have recovered from the radiation side-effects.\n* History of or radiological evidence of brain metastasis including previously treated, resected or asymptomatic brain lesions or leptomeningeal involvement.\n* Active seizure disorder or history of cerebrovascular accident (CVA) or transient ischemic (TI) attack within the past 12 months.\n* History of other malignancy within the last 3 years except for surgically cured non-melanoma skin cancer or cervical carcinoma in situ.\n* Active cardiac disease e.g. unstable angina, congestive heart failure, myocardial infarction (MI) within the preceding 6 months.\n* Any medical condition prohibiting standard imaging procedures\n* Pregnant or breast-feeding.\n* Any unrelated illness, e.g. active infection requiring parenteral antibiotics, inflammation, medical condition or laboratory abnormalities, which in the judgment of the investigator might significantly affect patients' study participation.\n* Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of either study drug.\n* Known hepatitis B/C or HIV (human immunodeficiency virus) infection.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}